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Abstract
Alu-mediated rearrangement of tumor suppressor genes occurs frequently during carcinogenesis. In breast cancer, this
mechanism contributes to loss of the wild-type BRCA1 allele in inherited disease and to loss of heterozygosity in sporadic
cancer. To identify genes required for suppression of Alu-mediated recombination we performed a genomewide screen of a
collection of 4672 yeast gene deletion mutants using a direct repeat recombination assay. The primary screen and
subsequent analysis identified 12 candidate genes including TSA, ELG1, and RRM3, which are known to play a significant role
in maintaining genomic stability. Genetic analysis of the corresponding human homologs was performed in sporadic breast
tumors and in inherited BRCA1-associated carcinomas. Sequencing of these genes in high risk breast cancer families
revealed a potential role for the helicase PIF1 in cancer predisposition. PIF1 variant L319P was identified in three breast
cancer families; importantly, this variant, which is predicted to be functionally damaging, was not identified in a large series
of controls nor has it been reported in either dbSNP or the 1000 Genomes Project. In Schizosaccharomyces pombe, Pfh1 is
required to maintain both mitochondrial and nuclear genomic integrity. Functional studies in yeast of human PIF1 L319P
revealed that this variant cannot complement the essential functions of Pfh1 in either the nucleus or mitochondria. Our
results provide a global view of nonessential genes involved in suppressing Alu-mediated recombination and implicate
variation in PIF1 in breast cancer predisposition.
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Introduction
Alu elements account for more than 10% of the human genome
[1] and consequently provide abundant opportunities for unequal
homologous recombination both intrachromosomally, resulting in
deletion or duplication of exons in a gene, and interchromoso-
mally, causing more complex chromosomal abnormalities. Thus, it
is not surprising that unequal homologous recombination between
Alu repeats contributes to a significant proportion of human
genetic disease [2].
Germline mutations in BRCA1 predispose to breast and ovarian
cancer. The 84-kb BRCA1 locus is densely packed with repetitive
elements including 138 individual Alu repeats that comprise 41.5%
of the total sequence [3]. While the majority of known BRCA1
mutations are small nucleotide sequence alterations (Breast Cancer
Information Core database, http://research.nhgri.nih.gov/bic),
mutations involving Alu sequences are common. To date, at least
81 large genomic rearrangements in BRCA1 have been identified
in high-risk breast cancer families, the majority of which are
deletions ranging in size from a few hundred base pairs, to tens
of kilobases. Of these, 59 are due to Alu-mediated unequal
homologous recombination [4]. Of the remaining characterized
deletions, 16 are the result of nonhomologous recombination
events, eight of which involve one Alu repeat at either the 59 or 39
breakpoint, and five are the result of recombination between
BRCA1 and the human BRCA1 pseudogene. Importantly, large
genomic rearrangements account for up to 12% of all novel
BRCA1 mutations identified in high-risk breast cancer families [5].
LOH at 17q has been detected in about 30%–60% of sporadic
breast tumors and, in many instances, includes the BRCA1 locus
[6–9]. Loss of heterozygosity at the BRCA1 locus has been
reported in 20%–70% of sporadic breast and ovarian cases [10–
14] and in breast cancers has been correlated with larger tumor
size, higher grade, and negative hormone receptor negative status
[15]. Thus, it is possible that Alu-mediated recombination in may
be responsible for a significant proportion of germline deletions
and/or rearrangements in BRCA1 as well as contribute to allelic
loss of BRCA1 in sporadic disease. However, the genes responsible
for suppressing Alu-mediated genomic instability remain unknown.
Previously, our lab exploited a functional assay in yeast to
search for mutations caused by deficiencies of the yeast homologs
of human mismatch repair genes [16]. These studies demonstrated
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e30748that yeast is a model organism for examining mutation rates in
known human tumor suppressor genes. We modified this
approach to investigate the mechanisms underlying Alu-mediated
unequal homologous recombination. Here we report the identi-
fication of yeast genetic backgrounds permissive for high frequency
Alu-mediated rearrangement at the BRCA1 locus. Because many
genes responsible for maintaining genomic stability are highly
conserved evolutionarily across species including yeast and
mammals [17,18], we characterized variation in the human
homologs of the yeast genes to determine whether mutation
contributes to either inherited and/or sporadic breast tumorigen-
esis. Our global analysis of non-essential genes involved in
suppressing Alu-mediated recombination has identified human
genes not previously known to be involved in maintaining genomic
stability. We present both genetic and functional data which
suggests that PIF1 may function as a tumor suppressor.
Materials and Methods
Plasmid construction
Primer sequences used for cloning purposes are listed in Table
S1. The BRCA1 intron 16 AluSp element (Genbank L78833;
58500–58798), was amplified from genomic DNA and cloned into
plasmid pCRH2.1-TOPOH using the TOPO TA CloningH
protocol (Invitrogen). Primer design incorporated restriction
enzyme target sequences for BamHI, AscI and NcoI to facilitate
cloning into pRS415, a centromeric vector with a LEU2 marker.
Following site-directed mutagenesis (GeneEditor
TM in vitro Site-
Directed Mutagenesis System; Promega) of an internal Nco1 site
in the URA3 gene from plasmid pRS416, the gene was amplified
with primers which incorporated flanking NcoI restriction
enzymes sites. Construction of Alu-URA-Alu pRS415 proceeded
as follows: the BamHI-flanked Alu element was ligated into
pRS415, followed by the AscI-flanked Alu element, and lastly, the
URA3 gene was cloned between the AluSp elements using the
engineered NcoI restriction sites. Escherichia coli TOP10 One ShotH
competent cells were used for initial bacterial transformations
while SUREH (Stop Unwanted Rearrangement Events) competent
cells were used for transformation and propagation of the final
construct, pAlu-URA-Alu (pAUA), Figure 1, which was sequenced
to confirm presence and orientation of inserts.
Functional screen for suppressors of Alu-mediated
recombination
The collection of haploid yeast deletion strains screened in this
study has been previously described [19]. All strains were
propagated at 30uC. Deletion strains were transferred using a
multipronged replica-plating device to 96-well plates containing
100 microliters of standard YPAD media supplemented with
10 mg/ml G418 and grown overnight. 30 microliters of each
culture was transferred to a fresh plate containing 80 microliters
of YPAD. After a five hour incubation period, yeast were
transformed with 200 ng of pAUA plasmid DNA using the
lithium acetate/PEG method [20–22]. Following transformation,
each well was individually plated onto selective medium (SC –
Leu/2Ura) and incubated at 30uC. After three days of growth,
individual colonies from each transformation were picked with a
sterile toothpick and diluted in 100 microliters dH2O. A total of 8
microliters of dilution culture was streaked onto SC –Leu/+5FOA
plates. Deletion of the URA3 gene in pAUA is permissive for
growth on 5FOA. Following a 3-day incubation, 5-FOA
R was
scored as follows: 0 colonies=0; 1–5 colonies=1; 6–10 colo-
nies=2; 11–15 colonies=3; 16–34 colonies=4; $35 colonies=5
(Figure S1). This screen was repeated and duplicate scores were
added together to generate an overall score for each deletion strain
of 0–10. Naı ¨ve strains with scores of 7–10 were retransformed and
re-screened. Suppressors of Alu-mediated recombination identified
in the BY4742 background were re-verified by analyzing their
counterparts in the BY4741 background. Identifying tag sequences
for stains were determined and compared to the tag lists on http://
www-sequence.stanford.edu/group/yeast_deletion_project/strain_
alpha_mating_type.txt or http://www-sequence.stanford.edu/
group/yeast_deletion_project/strain_ a _mating_type.txt. We ac-
knowledge that this screen would fail to reveal human genes
involved in suppressing Alu-mediated rearrangements for which
there are no homologs in budding yeast.
Fluctuation analysis
The Alu-mediated recombination rate for individual yeast
deletion strains was determined by fluctuation analysis using the
method of the median [23] as previously described [24,25]. In
brief, yeast successfully transformed with plasmid pAUA were
selected on SC –Ura/2Leu plates. For each fluctuation analysis,
ten individual colonies from each strain were each resuspended in
water and dilutions were plated on 2Leu
/+5FOA plates (to
measure 5-FOA
R) and 2Leu plates (to monitor viable cells). The
number of colonies on each plate was counted after three days of
growth at 30uC. Mutation rates represent 5-FOA
R events/cell
division. For each strain, fluctuation analysis was performed
independently three to four times with final mutation rates
determined by averaging individual results. Student’s t-test was
used to calculate p-values.
Human homolog identification
The entire yeast amino acid sequence for each gene was eva-
luated using BLASTp (http://www.ncbi.nlm.nih.gov/BLAST/).
To be considered the human homolog of the respective yeast gene,
human genes had to have an e value greater than e-28. Genomic
sequences of human homologs were obtained using the Univer-
sity of Santa Cruz Genome Database (http://www.genome.ucsc.
edu).
Figure 1. Alu-URA-Alu pRS415 (pAUA). A construct containing a
URA3 gene flanked by identical AluSp repetitive elements was inserted
into the low-copy-number yeast plasmid pRS415.
doi:10.1371/journal.pone.0030748.g001
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Human DNA samples evaluated in this study were from (a) a
cohort of 44 Ashkenazi Jewish probands from families with at least
four cases of breast cancer and no known mutations in the high
risk breast cancer genes BRCA1, BRCA2, and CHEK2 [5], (b) a
cohort of 94 women with known BRCA1 mutations who developed
breast cancer at or before the age of 39 and/or ovarian cancer at
or before the age of 64 [5], (c) a series of 196 Ashkenazi Jewish
controls, (d) a series of 200 Caucasian controls, (e) a series of an
additional 900 Ashkenazi Jewish breast cancer cases [5], and (f) a
series of 400 additional high risk breast cancer probands [5]. All
cancer diagnoses were verified by pathology reports and/or
hospital records. The study was approved by the University of
Washington Human Subjects Division (IRB protocol 34173). All
participants provided informed consent.
Loss of heterozygosity of candidate genes in sporadic
breast cancers
Tumor specimens were obtained from the Cooperative Human
Tissue Network. Microsatellite markers flanking each human
homolog were chosen using the University of Santa Cruz Genome
Database (http://www.genome.ucsc.edu). Table S2 lists the mic-
rosatellite markers used to evaluate loss of heterozygosity in a
series of 25 sporadic grade III breast tumors. Haematoxylin and
eosin stained sections from formalin-fixed paraffin-embedded
tissues were reviewed prior to DNA extractions. Tumor DNA
from regions displaying greater than 70% neoplasticity and
normal DNA was extracted using the PicoPure
TM DNA
Extraction Kit (Arcturus Bioscience). PCR reactions included
500 microCi [alpha-
32P] dCTP. PCR products were separated by
capillary electrophoresis using 6% polyacrylamide gels. The gels
were dried under vacuum and exposed to x-ray film. For all
heterozygous alleles, LOH was defined as loss of $50%
radioactive intensity in tumor DNA compared to normal.
Genomic sequencing
Sequencing primers were designed using the MacVector
software (version 7.2) so that all exonic and at least 20 base pairs
of flanking intronic sequence were evaluated. Primer sequences
are available upon request. Total genomic DNA was extracted
from Epstein-Barr virus-immortalized lymphoblast cell lines using
the Puregene DNA extraction system (Gentra). PCR reactions
consisted of 100 ng of genomic DNA, 10 pmole of each primer,
200 microM of dATP, dTTP, and dGTP, dCTP, 1X PCR Buffer
(Invitrogen), 1.5 mM MgCl2, and 1 unit Taq polymerase
(Invitrogen). PCR products were purified and then bidirectionally
sequenced on either an ABI 3100 or ABI 3730 DNA Analyzer.
Resulting DNA sequence was analyzed using either Sequencing
Analysis (version 3.3) or Sequencher
TM (version 4.2).
Substitution tolerance and protein structure prediction
Amino acid substitutions were characterized with two computer
resources to predict if they were deleterious: SIFT (Sorting Intolerant
from Tolerant) (http://blocks.fhcrc.org/sift/SIFT.html or http://sift.
jcvi. org/sift-bin) and PolyPhen (Polymorphism Phenotyping) (http://
genetics.bwh.harvard.edu/pph/). Secondary structure elements were
predicted using PSIPRED (http://bioinf.cs.ucl.ac.uk/psipred/) and
PredictProtein (http://www.predictprotein.org/) programs.
Cross complementation assays in Schizosaccharomyces
pombe
Strain genotypes are listed in Table S3. Schizosaccharomyces pombe
(S. pombe) cells were cultured in supplemented yeast extract (YES,
Difco) or supplemented Edinburgh minimal medium [26] at 32uC,
unless otherwise noted. Leucine 430 (codon TTA) was mutated to
proline (codon CCG) by site-directed mutagenesis (Stratagene) on
a vector carrying a leu
+ marker. Using a rapid transformation
method [27], pfh1-L430P was integrated at the leu1-32 locus of a
strain containing loxP pfh1
+ kanMX6 loxP at the endogenous pfh1
locus. Strains were grown to log phase in supplemented liquid
Edinburgh minimal medium. A rapid transformation protocol
[27] was used to introduce either pREP82 cre (cre
+) or pREP82 cre
(Y324F) (cre
2) [28]. The Y324F point mutation abolishes catalytic
activity of Cre recombinase which promotes recombination at
loxP sites. Transformation plates were typically incubated at 32uC
for 4 days except plates with pfh1-mt* which were incubated at
18uC for 6 days and 30uC for 3 days. For western blot analysis,
pfh1-L430P was integrated at the leu1-32 locus of a strain
containing nmt 81 pfh1
+ GFP at the endogenous pfh1 locus. Pfh1-
GFP was depleted by the addition of 30 mM thiamine over
24 hours. Whole cell extracts were prepared by glass bead lysis in
HB buffer [26], containing a protease inhibitor cocktail (Roche).
Protein concentration was determined by BCA protein assay kit
(Pierce) and 200 mg of total protein was loaded onto a 7.8% SDS-
PAGE. Blots were probed with rabbit anti-Pfh1 polyclonal serum
[29] and HRP-conjugated goat anti-rabbit IgG polyclonal serum
(BioRad).
Results
A genome-wide screen in S. cerevisiae for suppressors of
Alu-mediated rearrangements
There are 11 subfamilies of Alu elements in the BRCA1 gene that
differ in sequence and in length [3]. The pAUA construct was
created using a BRCA1 AluSp sequence (Genbank L78833 58500–
58798) as this subfamily has been shown to be frequently involved
in BRCA1 genomic rearrangements. The URA3 gene was inserted
between these Alu elements to allow for selection. The resulting
plasmid (pAUA, Figure 1) was transformed into the complete set of
tagged deletion strains from the Saccharomyces cerevisiae Genome
Project. A direct repeat recombination assay marked by loss of
URA3 expression was performed with URA3 deficient strains
identified by their ability to grow on plates containing the drug 5-
FOA. Resistance to this drug (5-FOA
R) was scored as described in
Materials and Methods (Figure S1). The total collection contains
4672 deleted strains in the BY4742 background of which 4634
(99.2%) were successfully screened using this approach. Results of
this screen are summarized in Table S4. Overall, 548 strains
(11.8%) had a score of 8 or greater. Naı ¨ve yeast from these 548
deletion strains were retransformed with pAUA and 5-FOA
R
colonies scored. Mutation rates for the 66 deletion stains with
scores of 7 or higher were determined by fluctuation analyses and
compared to the parental strain mutation rate. Table 1 lists the 12
yeast deletion strains with Alu-mediated rearrangement rates of
greater than 1.5 fold over that of wild-type. Mutation rates ranged
from 1.5 to 10.6 fold higher than that of the wild-type mutation
rate. Deletion cassette tags for these strains were sequenced to
confirm strain assignment.
To determine whether loss of URA3 expression was the result of
Alu-mediated recombination between direct repeats as opposed to
other mechanisms (e.g. point mutation), pAUA plasmids were
rescued from 5-FOA
R colonies from strains with mutation rates
greater than 1.5 fold that of wild-type. In all 12 strains, sequencing
of rescued plasmids revealed constructs that retained only one Alu
element, confirming that the mechanism responsible for loss of
URA3 expression was deletion of genomic sequence via Alu-
mediated rearrangement.
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strains of the twelve potential mutator genes in the BY4741
background were transformed with the reporter plasmid and
fluctuation analyses performed. Mutation rates were calculated and
compared to wild-type BY4741. Mutation rates for strains YJL088W
(arg3), YHR031C (rrm3), YML028W (tsa1), and YKR087C (oma1)
were greater than 1.5 fold that of wild-type (Table S5).
Identification of human homologs for yeast genes that
suppress Alu-mediated unequal homologous
recombination
In order to identify potential human homologs of yeast genes,
amino acid sequences corresponding to the deleted yeast genes
were compared using BLASTp to all Homo sapiens proteins. Table 1
lists the potential human homologs, and Table S6 provides their
BLASTp e-values, human chromosomal locations, and a brief
description of function for each protein. Note that yeast Tsa1 has
four potential human homologous: PRDX1, PRDX2, PRDX3, and
PRDX4. As expected, some yeast genes did not have an identifiable
human homolog. Human homologs corresponding to yeast genes
with mutation rates above 1.8 fold in BY4742 deletion strains were
used in subsequent studies. These human genes were: OTC,
PRDX1, PRDX2, PRDX3, PRDX4, PIF1, OMA1, and FANCM.
Novel variants in suppressors of Alu-mediated
recombination do not modify BRCA1-associated cancer risk
Among carriers of BRCA1 mutations, there is significant
variability in the age of onset of cancer [30–32]. Studies of high-
risk families quantifying the extent of risk variation have suggested
that other genetic factors may modify the risk of breast cancer
associated with BRCA1 mutations [33–35]. Importantly, it is likely
that initiation of a significant proportion of neoplastic transfor-
mation in mutation carriers is the result of Alu-mediated aberrant
homologous recombination events resulting in somatic loss of the
wild-type allele. In order to determine if variation in candidate
genes modifies the effect of germline mutation in BRCA1, women
with inherited mutations in BRCA1 who developed breast cancer
at or before the age of 39 and/or ovarian cancer at or before the
age of 64 were identified from a large series of BRCA1 mutation
carriers. Genomic sequence for the eight candidate genes was
determined using DNA from the selected 94 BRCA1 mutation
carriers. Polymorphisms listed on the UCSC Genome Browser as
known SNPs or reported in the 1000 Genomes Project were not
considered further. Eleven novel heterozygous variants in these
human homologs were identified (Table 1 and Table S7): one in
PRDX3, one in PRDX4, two in PIF1, one in OMA1, and six in
FANCM. No novel variants were identified in OTC, PRDX1, or
PRDX2. The novel protein variants in PRDX3 and OMA1 were
predicted to be benign by Polyphen and SIFT, computational
tools used to predict if amino acid substitutions are deleterious. All
six novel variants in FANCM were also predicted to be benign by
SIFT and PolyPhen; in addition two of these mutations were
identified in controls. The V21L mutation in PIF1 was also
predicted by PolyPhen and SIFT to be benign. The P109S
mutation in PIF1 was predicted to be probably damaging but was
identified in control populations. We also determined whether, in
a family in which a respective variant was found, whether all
BRCA1 mutation carriers in a family also carried the respective
variant allele. However, no variants segregated with BRCA1
carrier status in a given family. Thus, we conclude that these
variants did not modify risk of breast and/or ovarian cancer in
BRCA1 mutation carrier.
Table 1. Alu-mediated recombination rates and genetic analyses of candidate suppressors of Alu mediated recombination.
Yeast Gene Yeast ORF
Mutation Rate
610
26
Fold Induction
over WT p-value
Human
Homolog(s) BRCA1 modifiers
a LOH
b AJ screen
c
Additional
screening
d
ARG3 YJL088W 45.0 10.61 0.055 OTC No Mutations 6/20 No Mutations
ELG1 YOR144C 19.5 4.60 0.041 none
TSA1 YML028W 14.2 3.34 0.001 PRDX1 PRDX2
PRDX3 PRDX4
No Mutations No
Mutations L181H
IVS3+3C/T
6/23 2/25 4/24 3/20 No Mutations No
Mutations No
Mutations No
Mutations
RRM3 YHR031C 12.0 2.82 0.018 PIF1 (C15orf20) V21L, P109S 2/22 L319P S223T, D314E,
P357L, R592C
orf YPR170C 11.8 2.79 0.079 none
OMA1 YKR087C 10.5 2.47 0.190 OMA1 D365N 0/25 No Mutations
MPH1 YIR002C 7.89 1.86 0.009 FANCM T176M, C182S,
N689S, Q1730P,
I1742V, V2014A
3/22 H1703R, I1742V
HSM3 YBR272C 7.89 1.86 0.010 none
REC104 YHR157W 7.34 1.73 0.0009 none
REC8 YPR007C 7.13 1.68 0.218 none
GOR1 YNL274C 7.04 1.66 0.145 GRHPR
TEL1 YBL088C 6.44 1.52 0.054 ATM
Wild-type BY4742 4.24 1.00
aUnreported heterozygous mutations within each gene screened for in women with early breast and/or ovarian cancer and with BRCA1 mutations.
bNumber of sporadic breast tumors with loss of heterozygosity (LOH) of markers within or near each gene.
cUnreported heterozygous mutations within each gene screened for in Ashkenazi Jewish families with breast cancer but without mutations in the known breast cancer
genes.
dUnreported heterozygous mutations within PIF1 in a series of 400 additional high-risk breast cancer probands with no mutations in the known breast cancer genes.
doi:10.1371/journal.pone.0030748.t001
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recombination in sporadic breast tumors
Tumor suppressor genes often show evidence of heterozygous
gene loss in cancers. For example, loss of heterozygosity (LOH) at
BRCA1 is common in both inherited and sporadic breast cancer.
In order to determine if any of the genes identified in this screen
are candidate breast cancer tumor suppressor genes, twenty-five
sporadic breast tumors were analyzed for LOH at the respective
candidate gene loci. Two microsatellite markers for each gene
(Table S2) were amplified using tumor and corresponding normal
DNA. Results are listed in Table 1 (and shown in Figure S2). Of
the loci evaluated for LOH in breast tumors, the Arg3 homolog,
OTC, displayed LOH in 30% of breast tumors, while the Tsa1
homolog, PRDX1, was lost in 26% of tumors. For each tumor that
displayed LOH, the gene of interest was sequenced in order to
identify inactivating mutations on the retained allele. However, no
inactivating somatic mutations were identified, suggesting that
PRDX1 and OTC do not play a role in sporadic breast
tumorigenesis.
Analysis of suppressors of Alu-mediated recombination
in probands from high-risk breast cancer families
In order to determine if any of the genes revealed in our screen
contributed to increased risk in unexplained high-risk breast
cancer families, defined as families with 4 or more cases of breast
or ovarian cancer, we chose to study a population where genetic
heterogeneity is reduced. Genomic DNA from probands of 44
Ashkenazi Jewish high-risk breast cancer families (wild-type for
BRCA1, BRCA2 and CHEK2) was sequenced. Polymorphisms listed
on the UCSC Genome Browser, dbSNP, or 1000 Genomes were
not considered to be new mutations. Three previously unreported
substitutions were identified, two in the FANCM gene, and one in
the PIF1 gene (Table 1 and Table S8). The mutations in FANCM
were identified in the control series and thus were not considered
to contribute to elevated breast cancer risk. However, the
heterozygous PIF1 variant L319P was not found in a series of
184 Ashkenazi Jewish controls or in 184 Caucasian controls. Both
SIFT and PolyPhen indicated that this substitution was likely to be
deleterious. This variant was identified in a family in which the
proband had breast cancer at the age of 37. The substitution was
inherited from the proband’s father who was diagnosed with
prostate cancer at 60. The proband’s paternal grandmother also
carried the variant and was diagnosed with breast cancer at 63.
Interestingly, her paternal aunt who also carried the variant was
diagnosed with extramammary Paget’s disease in the genital area.
This condition is an exceedingly rare intraepithelial adenocarci-
noma and is often associated with neoplasms arising in the
bladder, urethra, or prostate (reviewed in [36]).
Because this family is of Ashkenazi Jewish ancestry, we screened
normal DNA from an additional 844 Ashkenazi Jewish breast
cancer cases for PIF1 L319P and identified two probands
who carried this allele. Of note, PIF1 L319P was not detected in
almost 10,000 chromosomes evaluated in the Exome Variant
series (http://evs.gs.washington.edu/EVS). We also determined
the sequence of the entire PIF1 coding sequence and 20 bp of
flanking intronic sequence in normal DNA from 400 additional
high-risk breast cancer probands from of European ancestry. For
all probands, BRCA1 and BRCA2 had been determined to be
wildtype on the basis of commercial sequencing and BART
analysis by Myriad Genetics [37]. Although PIF1 variant L319P
was not observed in this series, four novel heterozygous variants
were identified (Table 2). All PIF1 variants identified to date are
listed in Table 2. Of the additional variants, only the S223T and
R592C substitutions were predicted to be intolerable by both
SIFT and PolyPhen.
Bioinformatic analysis of human PIF1 variant L319P
Protein alignment with PIF1 homologs places PIF1 L319
between conserved helicase motifs II and III [38]. Amino acid
L319 is 93% conserved with only one noted conservative
substitution in Chlamydia muridarum. To determine if the PIF1
L319P variant impacts protein structure, bioinformatic resources
were used to evaluate conservation of the amino acid in which the
Table 2. PIF1 variants.
Heterozygous
Mutation
# of
families
Frequency
in controls
SIFT
a
del?
b align.
c
PolyPhen
score D
d prediction
e
1000
Genomes dbSNP Exome Variant
Secondary Structure
g
prediction confidence
V21L 1 0/200
h 0.16 0.41 1.465 Benign Not present Not present Not present Strand 9
P109S 1 1/198
h 0.05 0.49 2.506 Probably damaging Not present Not present 0.005 EA 0.001 AA Coil 9
S223T 1 0.01 0.96 1.544 Possibly damaging Not present Not present 0.001 EA 0.0003 AA Coil 1
D314E 1 0.42 0.98 0.366 Benign Not present Not present Not present Helix 8
L319P 3 0/184
h 0/184
i 0.00 0.99 2.139 Probably damaging Not present Not present Not present Helix 9
P357L 1 0.18 0.98 1.716 Possibly damaging Not present Not present 0.0000 EA 0.002 AA Coil 9
R592C 1 0.01 0.99 2.913 Probably damaging R592H R592H;
rs114090726
0.0004 EA 0.0000 AA Strand 9
aPIF1: gi for SIFT prediction is 82546872; protein identifier for PolyPhen prediction is Q330H5.
bSIFT prediction probability of deleterious allele (,0.05 is deleterious).
cSIFT alignment score (1.00 is highest).
dPolyPhen Position-Specific Independent Counts (PSIC) profile score difference (large values may indicate that the studied substitution is rarely or never observed in the
protein family).
ePolyPhen prediction.
fExome variant database: EA=European Americans; AA=African Americans.
gPredicted secondary structure using PSIPRED (confidence level 0=low; 9=high).
hCaucasian control group.
iAshkenazi Jewish control group.
doi:10.1371/journal.pone.0030748.t002
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prediction program predicted with a high confidence level that
amino acid L319 is in the middle of a helix.
Functional analysis of human PIF1 variant L319P in yeast
S. pombe Pfh1 is required to maintain both mitochondrial and
nuclear genome integrity [39]. The S. pombe Pfh1 allele L430P
corresponds to the H. sapiens L319P allele. To determine if a pfh1-
L430P allele could provide the essential function of pfh1
+ in S.
pombe, three different strains were constructed (Table S3). All three
strains had a wild-type (WT) pfh1
+ flanked by loxP sites at its
endogenous locus. When WT Cre recombinase was introduced
into these strains, it stimulated recombination between the two
loxP sites flanking pfh1+, resulting in a pfh1 cell. The strains also
carried either pfh1-L430P, wild-type pfh1
+, or an empty vector
integrated at the leu1-32 locus. The ectopic copies of mutant
or WT pfh1 were expressed from the pfh1
+ promoter. Cre
recombinase was introduced into the three strains by introducing
a plasmid containing cre
+ and ura4
+. In addition, the three strains
were independently transformed with a plasmid containing ura4
+
and a catalytically inactive Cre recombinase (cre
2), which served
as a control for transformation efficiency [28].
Strains expressing pfh1-L430P produced very few Ura
+ colonies
when transformed with cre
+ (Figure 2A, top row left). However, a
large number of Ura
+ transformants were observed with the
catalytically inactive cre
2 control (Figure 2A, second row left).
Similar results were seen with the negative control strain in which
very few Ura
+ transformants were seen with an empty vector at the
leu1-32 locus, and very few Ura
+ colonies were obtained with the
cre
+ plasmid and many Ura
+ cells with the cre
2 control (Figure 2A
first and second rows right). In contrast, in the positive control
strain having pfh1
+ at leu1-32, large numbers of Ura
+ transfor-
mants were observed after transformation with either cre
+ or cre
2
recombinase plasmids (Figure 2A first and second rows middle).
Further analysis of the resulting colonies from the cre
+ transfor-
mation of the pfh1-L430P and empty vector revealed that they
were kanamycin resistant, indicating that wild-type Pfh1 was
expressed in these transformants due to lack of recombination at
the loxP sites.
The pfh1-L430P allele could fail to support viability either
because the mutant protein is non-functional or because it is not
stably maintained. To distinguish between these possibilities,
strains expressing GFP-tagged Pfh1 at its endogenous locus and
Pfh1-L430P at the leu1-32 locus were employed (Table S3). Since
degradation products from Pfh1-GFP overlapped with the Pfh1-
L430P bands on a western blot, Pfh1-GFP from an nmt
+
repressible promoter system was used so that its expression could
be turned off by addition of thiamine. The western blot revealed
that Pfh1-GFP was not expressed in the presence of thiamine (WT,
Figure 2B), whereas Pfh1-L430P expression was seen in three of
three independent clones (1–3, Figure 2B).
Separation of function alleles pfh1-nuc and pfh1-mt* produce
protein that localizes to the nucleus and mitochondria, respectively
[39]. To determine whether pfh1-L430P can complement either
the nuclear or the mitochondrial helicase function, strains with
pfh1-nuc or pfh1-mt* allele were used for a second complementation
experiment (Table S3). Similar to the experiment in Figure 2A,
pfh1-nuc or pfh1-mt* strains contained WT pfh1
+ flanked by loxP
sites and pfh1-L430P expressed under its endogenous promoter at
the leu1-32 locus. After the transformation of Cre recombinase,
few Ura
+ transformants were observed (Figure 2C, top row). In
contrast, the transformation control (cre
2) yielded many Ura
+
colonies (Figure 2C, bottom row). From this data, it can be
concluded that the point mutation pfh1-L430P cannot complement
the essential function of Pfh1 in either the nucleus or the
mitochondria.
Discussion
BRCA1 is a classic tumor suppressor gene in that loss of the
wild-type allele (loss of heterozygosity, LOH) is required for
tumorigenesis in germline mutation carriers. In sporadic breast
Figure 2. pfh1-L430P does not complement wild-type pfh1
+
function. (A) Complementation assay in pfh1::loxP pfh1
+ kanMX6 loxP
strain with either the L430P mutation (leu::pfh1-L430P), Pfh1 (leu::pfh1
+),
or an empty vector (leu::leu
+) strain after transformation with a plasmid
expressing Cre (cre
+) or Cre-Y324F (cre
2). The transformation plates are
contrast-inverted pictures. (B) Anti-Pfh1 western blot of wild-type
Pfh1GFP (WT) and three independent clones (1–3) expressing Pfh1-
L430P. S. pombe cells were grown in the absence (2) or presence (+)o f
thiamine. 0, 12, and 24 hours indicates the amount of time cells were
grown in the presence of thiamine. The loading control (LC) is a non-
specific background band. (C) Heterologous expression constructs of
pfh1-nuc or pfh1-mt* are indicated in the presence of pfh1::loxP pfh1
+
kanMX6 loxP and leu::pfh1-L430P. Contrast-inverted pictures of trans-
formation plates with cre
+ on the top and cre
2 on the bottom.
doi:10.1371/journal.pone.0030748.g002
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model would have predicted that in at least a proportion of these
cases, BRCA1 is inactivated by a somatically acquired mutation.
Contradicting this hypothesis is the observation that somatic
BRCA1 mutations are exceedingly rare in sporadic carcinomas.
However, BRCA1 message and protein are often decreased in
sporadic breast and ovarian cancers [13,14,40,41]. In some cases,
BRCA1 is down-regulated by aberrant methylation. Methylation
of the BRCA1 promoter occurs in 11–14% [42–44] of sporadic
breast cancers and in 5–31% [42,44–46] of ovarian cancers and is
often associated with LOH [42,47]. However, other mechanisms
responsible for loss of BRCA1 in sporadic disease remain to be
determined.
Alu-mediated aberrant homologous recombination contributes
to loss of BRCA1 in a significant proportion of inherited disease.
Importantly, this mechanism may explain some of the allelic loss of
BRCA1 observed in sporadic disease. Thus we have taken a
genomewide approach to identify genes that suppress Alu-
mediated recombination in yeast with the knowledge that this
screen would fail to reveal any human genes involved in
suppressing Alu-mediated recombination for which no human
homologs are present in yeast. A functional screen of the complete
set of yeast deletion strains in the BY4742 background identified
twelve strains with Alu-mediated recombination rates greater than
1.5 fold that of the wild-type strain (Table 1). To confirm that the
5-FOA
R phenotype of the newly identified suppressors of Alu-
mediated recombination was the result of deletion of the given
open reading frames (ORFs), their counterparts in the BY4741
background were analyzed. Only 4 of the 12 strains were validated
in BY4741, raising the possibility that the increased rate of Alu-
mediated recombination in the other 8 strains was not related to
deletion of the indicated gene. Of the 4 validated strains, mutation
rates for arg3, tsa1, and rrm3 were significant when compared to the
respective wild-type rate. While the mutation rate between oma1 in
BY4741 and BY4742 was consistent, suggesting that this gene has
a role in suppressing Alu-mediated recombination, the corre-
sponding p-values were not significant when compared to the
respective wild-type strain.
Deletion of TSA1, a thioredoxin peroxidase, has been shown to
increase the rate of both spontaneous mutation as well as gross
chromosomal rearrangement (GCR) [48,49]. The relative rate of
tsa1-permissive GCR is similar to that for Alu-mediated recombi-
nation (7 and 3.34 [49], and this study, respectively). Together
these results indicate the importance of this gene in preventing a
broad spectrum of types of genomic instability. The human
homologs of TSA1 are the four member of the peroxiredoxin
(PRDX) family of antioxidant enzymes which reduce hydrogen
peroxide and alkyl hydroperoxides. Homozygote Prdx1
2/2 mice
knockouts develop hemolytic anemia and several malignant
cancers including epithelial and mesenchymal tumors such as
hepatocellular carcinoma, fibrosarcoma, osteosarcoma, islet cell
adenomas, and adenocarcinomas of the lung and breast [50].
Heterozygote Prdx1
+/2 mice also show increased frequency of
hemolytic anemia and malignant cancer.
In contrast, ARG3, an ornithine carbamoyltransferase involved
in the biosynthesis of arginine [51] and its human homolog OTC
(ornithine transcarbamylase) have not been priorly identified as
having a role in maintaining genomic stability. In addition, this
protein has not been associated with cancer.
The final human homolog validated in this screen, RRM3, was
first identified as a suppressor of recombination in ribosomal DNA
(rDNA) [52]. S. cerevisiae RRM3 and its paralog, PIF1, belong to
the super family IB of 59-to-39 directed DNA helicases. The Pif1
family helicases are defined by seven highly conserved helicase
signature motifs, three motifs that are shared with E. coli RecD and
in eukaryotes, and a highly conserved 21-residue Pif1 family
signature sequence located between motifs II and III [53]. Mouse
and human PIF1 proteins immuno-precipitate with telomerase
activity and TERT, the catalytic subunit of telomerase [54]. There
is also some data suggesting that, like yeast Pif1, human PIF1 may
inhibit telomerase activity in vivo and in vitro [38].
To determine whether variation in the human homologs of
yeast genes that suppress Alu-mediated recombination modify the
effect of BRCA1 in mutation carriers, we determined the sequence
of these genes in a series of BRCA1 mutation carriers who had
breast cancer and/or ovarian cancer at particularly early ages. Of
the eleven variants identified in BRCA1 mutation carriers, two
were identified in controls, and eight of the remaining mutations
were not predicted to be damaging by internal alignment
programs. Thus, the variants identified in these candidate genes
do not appear to contribute to particularly early onset of disease in
BRCA1 mutations carriers.
Numerous genomewide studies have been conducted analyzing
LOH in sporadic breast cancers to reveal foci of potential tumor
suppressor genes. Recent studies have employed higher resolution
array-based CGH (aCGH) showing the enormous complexity of
breast cancer genomes. These studies have consistently reported
the same large regions of loss (8p, 9p, 13q, 16q) [55–58]; the
number and identity of tumor suppressor genes that contribute to
sporadic breast cancer remains largely unknown. Interestingly,
high resolution mapping of regions of losses with frequencies of
.30% included 1p32.1-p31.1, which contains OMA1, 1p36.33-
p34.2, which is very close to PRDX1, 10q25.3-qtel, which contains
PRDX3, 15q21.3-q24.3, which contains PIF1, and 11q14.3-qtel,
which includes ATM [59]. In the present study, LOH analysis of
the human homolog suppressors of Alu-mediated recombination in
25 grade 3 invasive ductal carcinomas revealed LOH at 26 of 181
loci (14%), among informative cases. LOH frequencies among the
chromosomal regions varied from 0% to 30% (Table 1 and Figure
S2). For all genes displaying LOH, the retained allele was
sequenced to identify inactivating mutations; however, none were
identified in this series.
A significant proportion of high-risk breast cancer families are
not explained by mutations in known genes, indicating that still
unidentified genes may explain cancer risk in these families. To
determine if variation in the human homologs of the yeast mutator
candidate genes contributes to increased breast cancer risk in high-
risk families, a cohort of Ashkenazi Jewish probands was
sequenced for each of the human homologs. Three unreported
variants in candidate genes were identified in this population
(Table 1 and Table S8). Of these, only variant L319P in PIF1 was
reported to be damaging by PolyPhen and not tolerated by SIFT.
While this variant was not observed in 368 controls nor has it been
reported in dbSNP or the 1000 Genomes Project, we identified it
in 2 out of 844 breast cancer cases of Ashkenazi Jewish ancestry.
The leucine at amino acid 319 is completely conserved within the
PIF1 family of DNA helicases and is located within the putative
Pif1family signature motif located between motifs II and III [53].
Given that it is predicted to be within a helical domain
(PredictProtein and PSIPRED), substitution of the five-membered
chemical ring of proline from a linearly structured leucine likely
disrupts protein structure. However, given the number of
Ashkenazi Jewish controls evaluated for L319P we cannot exclude
the possibility that this allele may be a rare PIF1 allele limited to
this population.
Snow et al., reported that Pif1 (2/2) mice are viable at
expected frequencies and displayed no visible abnormalities or
increases tumor burden. These results seem to contradict those
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to breast carcinogenesis. However, for many genes it is well known
that findings in mouse mutants cannot necessarily be extrapolated
to humans. For example, early attempts to develop mouse models
of BRCA1-linked breast cancer were unsuccessful (reviewed in
[60]). Early embryonic lethality precluded tumor development in
Brca1 (2/2) mice. Surprisingly, conventional null or hypomor-
phic Brca1 alleles revealed lack of tumor formation in heterozy-
gous mice. However, homozygous mice with certain hypomorphic
Brca1 alleles can survive to adulthood and display an increased
susceptibility to a range of tumors, including mammary carcino-
mas [61]. Tumors can also be induced by conditional inactivation
of Brca1 in breast epithelial cells through cre/loxP-mediated
recombination [62]. Inactivation of Brca1 alone in murine ovarian
surface epithelium resulted in an increased accumulation of
premalignant changes, but no tumor formation [63]. Importantly,
somatic loss of both Brca1 and p53 resulted in the rapid and
efficient formation of highly proliferative, poorly differentiated
estrogen receptor-negative mammary tumors that closely mimic
human BRCA-mutated breast cancers with basal-like phenotypes
[64] suggesting that other genetic events contribute to tumorigen-
esis. Approximately 50% of familial breast cancer remains
unresolved- that is disease cannot be explained by loss of function
mutations in known breast cancer genes. Thus other genes are
worthy of in-depth genomic analysis in unresolved families
regardless of their associated mouse phenotype.
To determine if additional PIF1 variants impact breast cancer
risk, we determined the complete PIF1 coding sequence in a series
of 400 additional high risk breast cancer probands largely of
European ancestry. Of the variants identified in this series, S223T,
P357L, and R592C are potentially deleterious (Tables 1 and 2). In
S. cerevisiae Rrm3, threonine occupies the position corresponding to
human S233 thus it is unlikely that this variant impacts human
PIF1 function; however, the amino acid is immediately adjacent to
conserved helicase motif I (a nucleotide binding motif also known
as ‘‘the Walker A box’’) and as such could affect ATPase activity.
The human proline at position 357 is adjacent to motif III and
completely conserved within the family. Thus it is possible the
nonconservative amino acid change P357L contributes to protein
destabilization. R592C is a relatively conserved amino acid
position (R or Q in humans, mice, both yeast Pif helicases, and
E. coli RecD). While this substitution results in an amino acid with
a smaller side chain, it is conservative in terms of hydrophilicity.
However, in yeast, mutations in this region tend to disrupt helicase
activity but not ATP binding or hydrolysis thereby impairing the
ability of the protein to couple conformational changes caused by
ATPase activity to DNA unwinding [65]. Finally, PIF1 variant
P109L, which was found in a BRCA1 mutation carrier with
particularly early onset breast cancer as well as in 1 of 198
controls, is predicted to be deleterious. Although this proline
resides over 100 residues upstream of motif I, it is completely
conserved from yeast to humans.
The Pif1 family of 59 to 39 DNA helicases is conserved from
yeasts to humans. While the Pif1 helicase function is dispensable in
S. cerevisiae and mouse, the S. pombe Pfh1 is essential in both
mitochondria and nuclei [39]. The results shown here demon-
strate that the pfh1-L430P allele does not provide the essential
activity of Pfh1 (Figure 2A). Since Pfh1-L430P is expressed, its
failure to complement is not due to misfolding and degradation of
the mutant protein (Figure 2B). Pfh1-L430P does not complement
Pfh1 helicase activity in either the nucleus or the mitochondrial
(Figure 2C). Therefore, we conclude the lethality of cells
expressing Pfh1-L430P is due to loss of helicase function in both
the nucleus and mitochondria.
Here we report the systematic analysis of the complete set of
yeast gene deletion mutants to identify genes required for
preventing Alu-mediated aberrant homologous recombination
events, providing a global view of these nonessential genes in
maintaining genome stability. We identified both previously
known suppressors of chromosomal rearrangements as well as a
number of novel genes. We provide genetic and functional
evidence that a rare, loss of function variant in the helicase PIF1
may elevate breast cancer risk. Finally, although the primary aim
of this research was to identify novel genes involved in genomic
rearrangement at the BRCA1 locus, the genes identified in this
screen may also contribute to chromosomal rearrangement at
other loci. As such, they should be considered as candidate genes
capable of facilitating cancer-inducing deletions, duplications,
translocations, and splice variations in other tumor types.
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Figure S1 Scoring of 2Leu/+5FOA plates with cells
transformed with pAUA. Four rows (48 wells) from each yeast
deletion transformation plate were streaked onto 2Leu/+5FOA
media. This plate is an example. 5-FOA
R scoring is noted to
illustrate scores of 0 (0 colonies), 1 (1–5 colonies), 2 (6–10 colonies),
3 (11–15 colonies), 4 (16–34 colonies), and 5 ($35 colonies). The
wild-type strain had a score of 1.
(TIF)
Figure S2 LOH in sporadic breast tumors. Twenty-five
sporadic breast tumors and matched normal DNA were tested for
loss of heterozygosity (LOH). Two markers closely flanking each
gene were tested and loss of heterozygosity at either marker
indicated LOH at the gene. The percentage of LOH at each gene
is indicated below the dot plot.
(TIF)
Table S1 Oligonucleotides used in the process of
creating and sequencing pAUA.
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Table S2 Microsatellite markers used for LOH analysis
in sporadic breast tumors.
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Table S4 Results of yeast deletion strain 5FOA screen
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Jewish breast cancer families.
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